Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer

Yao, Zhipeng; Qi, Chenxue; Zhang, Fan; Yao, Hong; Wang, Cheng; Cao, Xiaoxiang; Zhao, Chenhui; Wang, Zhichun; Qi, Min; Yao, Chengyun; Wang, Xiaoming; Xia, Hongping

doi:10.1016/j.actbio.2023.10.024

Cited by 5 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported that the combined blockade of CXCR4 and PD-1 enhanced the chemotherapeutic effect in metastatic PDAC (NCT02826486) ( 34 ). Nanoparticles-based preclinical studies also implied that the combination of CXCR4 inhibitor and anti-PD1 could enhance the immune response by increasing the infiltration of CD4+ T cells, CD8+ T cells and polarization of macrophages, thus significantly inhibiting the progression of PDAC ( 35 , 36 ). Therefore, it is necessary to early identify CXCR4-high expression patients, whose prognosis may benefit from the combination of CXCR4 and immunochemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis

Chu,

Zhong,

Zang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThe circulating tumor cells (CTCs) could be captured by the peptide functionalized magnetic nanoparticles (Pep@MNP) detection system in pancreatic ductal adenocarcinoma (PDAC). CTCs and the CXCR4 expression were detected to explore their clinical significance. The CXCR4+ CTCs, this is highly metastatic-prone stem cell-like subsets of CTCs (HM-CTCs), were found to be associated with the early recurrence and metastasis of PDAC.MethodsCTCs were captured by Pep@MNP. CTCs were identified via immunofluorescence with CD45, cytokeratin antibodies, and the CXCR4 positive CTCs were assigned to be HM-CTCs.ResultsThe over-expression of CXCR4 could promote the migration of pancreatic cancer cell in vitro and in vivo. In peripheral blood (PB), CTCs were detected positive in 79.0% of all patients (49/62, 9 (0–71)/2mL), among which 63.3% patients (31/49, 3 (0–23)/2mL) were HM-CTCs positive. In portal vein blood (PVB), CTCs were positive in 77.5% of patients (31/40, 10 (0–40)/2mL), and 67.7% of which (21/31, 4 (0–15)/2mL) were HM-CTCs positive CTCs enumeration could be used as diagnostic biomarker of pancreatic cancer (AUC = 0.862), and the combination of CTCs positive and CA19–9 increase shows improved diagnostic accuracy (AUC = 0.963). in addition, PVB HM-CTCs were more accurate to predict the early recurrence and liver metastasis than PB HM-CTCs (AUC 0.825 vs. 0.787 and 0.827 vs. 0.809, respectively).ConclusionsThe CTCs identified by Pep@MNP detection system could be used as diagnostic and prognostic biomarkers of PDAC patients. We identified and defined the CXCR4 over-expressed CTC subpopulation as highly metastatic-prone CTCs, which was proved to identify patients who were prone to suffering from early recurrence and metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%